PMID- 34105800
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20220531
IS  - 1440-1711 (Electronic)
IS  - 0818-9641 (Linking)
VI  - 99
IP  - 9
DP  - 2021 Oct
TI  - Helicase antigen (HAGE)-derived vaccines induce immunity to HAGE and 
      ImmunoBody(R)-HAGE DNA vaccine delays the growth and metastasis of HAGE-expressing 
      tumors in vivo.
PG  - 972-989
LID - 10.1111/imcb.12485 [doi]
AB  - The management of patients with triple-negative breast cancer (TNBC) continues to 
      pose a significant clinical challenge. Less than 30% of women with metastatic 
      TNBC survive 5 years, despite adjuvant chemotherapy and the initial higher rates 
      of clinical response that can be achieved with neoadjuvant chemotherapy. 
      ImmunoBody is a plasmid DNA designed to encode a human antibody molecule with 
      complementarity-determining regions engineered to express cytotoxic and helper 
      T-cell epitopes derived from the cancer antigen of interest. The helicase antigen 
      (HAGE) is a cancer testis antigen, which is expressed in TNBC. Herein, we have 
      identified a 30-amino-acid-long HAGE-derived sequence containing human leukocyte 
      antigen (HLA)-A2- and HLA-DR1-restricted epitopes and demonstrated that the use 
      of this sequence as a peptide (with CpG/incomplete Freund's adjuvant) or 
      incorporated into an ImmunoBody vaccine can generate specific 
      interferon-gamma-secreting splenocytes in HHDII(+) DR1(+) mice. T-cell responses 
      elicited by the ImmunoBody-HAGE vaccine were superior to peptide immunization. 
      Moreover, splenocytes from ImmunoBody-HAGE-vaccinated mice stimulated in vitro 
      could recognize HAGE(+) tumor cells and the human TNBC cell line MDA-MB-231. More 
      importantly, the growth of implanted HHDII(+) DR1(+) HAGE(+) Luc(+) B16 cells.
CI  - (c) 2021 The Authors. Immunology & Cell Biology published by John Wiley & Sons 
      Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, 
      Inc.
FAU - Nagarajan, Divya
AU  - Nagarajan D
AD  - Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, 
      Sweden.
AD  - John van Geest Cancer Research Centre, School of Science and Technology, 
      Nottingham Trent University, Nottingham, UK.
AD  - Centre for Health, Ageing and Understanding Disease, School of Science and 
      Technology, Nottingham Trent University, Nottingham, UK.
FAU - Pearson, Joshua
AU  - Pearson J
AD  - John van Geest Cancer Research Centre, School of Science and Technology, 
      Nottingham Trent University, Nottingham, UK.
AD  - Centre for Health, Ageing and Understanding Disease, School of Science and 
      Technology, Nottingham Trent University, Nottingham, UK.
FAU - Brentville, Victoria
AU  - Brentville V
AD  - Scancell Ltd, Biodiscovery Institute, University of Nottingham, University Park, 
      Nottingham, UK.
FAU - Metheringham, Rachael
AU  - Metheringham R
AD  - Scancell Ltd, Biodiscovery Institute, University of Nottingham, University Park, 
      Nottingham, UK.
FAU - Pockley, A Graham
AU  - Pockley AG
AD  - John van Geest Cancer Research Centre, School of Science and Technology, 
      Nottingham Trent University, Nottingham, UK.
AD  - Centre for Health, Ageing and Understanding Disease, School of Science and 
      Technology, Nottingham Trent University, Nottingham, UK.
FAU - Durrant, Lindy
AU  - Durrant L
AD  - Scancell Ltd, Biodiscovery Institute, University of Nottingham, University Park, 
      Nottingham, UK.
FAU - McArdle, Stephanie E
AU  - McArdle SE
AD  - John van Geest Cancer Research Centre, School of Science and Technology, 
      Nottingham Trent University, Nottingham, UK.
AD  - Centre for Health, Ageing and Understanding Disease, School of Science and 
      Technology, Nottingham Trent University, Nottingham, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210919
PL  - United States
TA  - Immunol Cell Biol
JT  - Immunology and cell biology
JID - 8706300
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Vaccines, DNA)
RN  - EC 3.6.4.13 (DEAD-box RNA Helicases)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/*immunology
MH  - *Cancer Vaccines/immunology
MH  - DEAD-box RNA Helicases/*immunology
MH  - Epitopes, T-Lymphocyte
MH  - HLA-A2 Antigen
MH  - Humans
MH  - Male
MH  - Mice
MH  - T-Lymphocytes
MH  - *Triple Negative Breast Neoplasms/genetics/therapy
MH  - *Vaccines, DNA/immunology
OTO - NOTNLM
OT  - helicase antigen
OT  - metastasis
OT  - treatment
OT  - triple-negative breast cancer
OT  - vaccine
EDAT- 2021/06/10 06:00
MHDA- 2021/10/26 06:00
CRDT- 2021/06/09 08:54
PHST- 2021/04/28 00:00 [revised]
PHST- 2021/05/27 00:00 [revised]
PHST- 2021/06/04 00:00 [revised]
PHST- 2020/02/25 00:00 [received]
PHST- 2021/06/07 00:00 [accepted]
PHST- 2021/06/10 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2021/06/09 08:54 [entrez]
AID - 10.1111/imcb.12485 [doi]
PST - ppublish
SO  - Immunol Cell Biol. 2021 Oct;99(9):972-989. doi: 10.1111/imcb.12485. Epub 2021 Sep 
      19.